EHA 2023 | BEYOND trial update: luspatercept in non-transfusion-dependent β-thalassemia
Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon, provides insight into the long-term results of the Phase II BEYOND trial (NCT03342404), evaluating luspatercept treatment in patients with non-transfusion dependent beta-thalassemia (NTDT). Prof. Taher discusses how patients receiving luspatercept continued to experience a sustained increase in their hemoglobin levels over time. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant and research funding: Novartis, Celgene Corp (Bristol Myers Squibb), Vifor Pharma, Pharmacosmos, Agis Pharmaceuticals
